Work

Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.7047

Authors: Moshe Talpaz, Jorge E. Cortes, Hagop M. Kantarjian, Neil P. Shah, Dale L. Bixby, Ian Flinn, Thomas J O'Hare, Simin Hu, Victor M. Rivera, Timothy Piers Clackson, Maureen G Conlan, Frank G. Haluska, Brian J. Druker, Michael W.N. Deininger, Michael J. Mauro

Institutions: University of Michigan, The University of Texas MD Anderson Cancer Center, University of California, San Francisco, Sarah Cannon, Tennessee Oncology, Huntsman Cancer Institute, ARIAD Pharmaceuticals (United States), OHSU Knight Cancer Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2468418559

Cites:

Cited by: 8

Related to: 10